Aptose Biosciences Inc (LTS:0UI8)
C$ 1.33 0 (0%) Market Cap: 10.54 Mil Enterprise Value: 98,000.00 PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

Q1 2022 Aptose Biosciences Inc Earnings Call Transcript

May 09, 2022 / 09:00PM GMT
Release Date Price: C$111.3
Operator

Welcome to the Aptose Biosciences Inc. Reports Result for the First Quarter 2022 Conference Call. My name is Darryl, and I will be your operator for today's call. (Operator Instructions) As a reminder, this conference is being recorded.

I will now turn the call over to Dan Ferry. Dan, you may begin.

Daniel Ferry
LifeSci Advisors, LLC - MD & Relationship Manager

Thank you. Good afternoon, and welcome to the Aptose Biosciences conference call to discuss financial and operational results for the first quarter ended March 31, 2022. Earlier today, Aptose issued a press release relating to these financial results. The news release, as well as related SEC filings are accessible on Aptose's website. Joining me on today's call are Dr. William G. Rice, Chairman, President and CEO; and Dr. Rafael Bejar, Senior Vice President, Chief Medical Officer.

Before we proceed, I would like to remind everyone that certain statements made during this call will include forward-looking statements within the meaning of U.S. and Canadian securities laws. Forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot